<DOC>
	<DOCNO>NCT00257309</DOCNO>
	<brief_summary>General objective : To compare efficacy safety primary angioplasty ( PA ) thrombolytic therapy ( TT ) treatment AMI patient &gt; =75 year old ST-segment elevation LBBB AMI &lt; 6 hour evolution without contraindication TT . Hypothesis : The therapeutical strategy base PA superior base initially TT patient &gt; =75 year old AMI . Participating Centers : 27 Spanish hospital perform &gt; 50 PA/year . Primary Endpoint ( PE ) : Incidence aggregate death cause , reinfarction disable stroke 30 day . There also 7 secondary endpoint ( SE ) . Procedure : Diagnosis inclusion/exclusion criterion -- &gt; Centralized randomization -- &gt; Treatment allocation 1 ) TT weight adjust TNK + unfractionated heparin 2 ) PA within 120 minute . Estimated Sample size recruitment time : 570 patient 19 month . Follow-up : Blinded evaluation event ( PROBE regulation ) specify PE SE 30 day 12 month . Quality control : 100 % variable follow-up review external CRO . Safety Committee Event Adjudication Committee form expert participate study .</brief_summary>
	<brief_title>Thrombolysis Versus Primary Angioplasty AMI Elderly Patients</brief_title>
	<detailed_description>Hypothesis study . In patient 75 year age AMI ST-elevation LBBB , treatment strategy base primary angioplasty superior treatment strategy base initial fibrinolytic therapy reduce incidence death , re-infarction disable CVA 30 day . This benefit maintain 12 month . Objectives General objective study . To compare efficacy safety primary angioplasty fibrinolytic treatment &gt; =75 year-old patient AMI eligible fibrinolytic therapy Spanish medical center active program primary angioplasty . Primary end point : Incidence combine end point all-cause death , re-infartion disable stroke 30 day Secondary end point : - All-cause death 30 day - Incidence combined end point all-cause death , disable CVA de novo heart failure 30 day - Incidence recurrent ischemia require emergency catheterization first 30 day - Cause death 30 day classify three group : 1 . Shock heart ( pump ) failure 2 . Mechanical complication ( rupture ) electromechanical dissociation 3 . Other cause ( include bleed ) - Incidence major bleed hospital admission - All-cause mortality 12 month - Period time elapse presentation composite all-cause death , reinfarction disable CVA 12 month - Period time elapse presentation composite all-cause death , reinfarction , disable CVA non-elective hospital readmission cardiac cause ( unstable angina , heart failure , non-elective coronary revascularization 12 month . TYPE AND DESIGN OF THE CLINICAL TRIAL Clinical trial status Phase IV trial Description randomization process The treatment strategy determine centralized randomization process , use telephone system . Eligible patient randomize one two ( 2 ) treatment arm : fibrinolytic treatment primary angioplasty . Control design This randomized multicenter , open blind clinical trial design compare efficacy safety primary angioplasty vs. thrombolytic treatment &gt; =75 year-old patient AMI ST-elevation de novo LBBB , eligible thrombolysis , admit Spanish medical center active primary angioplasty program , within first 6 hour symptom onset . Masking technique Being open trial mask technique , emergency open procedure emergency code . Pre-inclusion / clearance period Not applicable SUBJECT SELECTION Inclusion / exclusion criterion Subjects must &gt; =75 year age AMI ST-elevation de novo LBBB , eligible thrombolytic therapy , admit Spanish medical center active primary angioplasty program within first 6 hour symptom onset . Each patient must fulfill inclusion criterion none exclusion criterion . Inclusion criterion : 1 . Subjects 75 year age 2 . Diagnosis AMI : chest pain symptom myocardial ischemia , least , 20 minute duration , respond nitrate therapy , evolution period le 6 hour symptom onset randomization process , , least , one follow alteration : 1 . ST-elevation &gt; =2 mm 2 precordial lead 2 . ST-elevation &gt; =1 mm 2 anterior lead 3 . Complete de novo ( probably de novo ) leave bundle branch block ( LBBB ) 3 . Subject able give inform consent prior randomization process agree fulfill procedure describe protocol , include follow-up hospital discharge . A write consent sign close relative witness also acceptable . Exclusion criterion : 1 . Documented contraindication use fibrinolytics . 1.1 . Internal active bleeding know history hemorrhagic diathesis 1.2 . History previous CVA kind time 1.3 . Intracranial tumor , arteriovenous malformation , aneurysm cerebral aneurysm repair 1.4 . Major surgery , parenchymal biopsy , ocular surgery severe traumatism 6 week prior randomization 1.5 . Unexplained puncture non-compressible vascular location last 24 hour prior randomization 1.6 . Confirmed arterial hypertension reliable measurement systolic AP &gt; 180 mmHg diastolic AP &gt; 110 mmHg 1.7 . Known thrombocytopenia &lt; 100.000 platelets/mL 1.8 . Prolonged ( &gt; 20 minute ) traumatic cardiopulmonar resuscitation ( CPR ) 2 week prior randomization 1.9 . History sign suggest aortic dissection 2 . Cardiogenic shock 3 . Estimated door-to-needle time &gt; 120 minute 4 . Administration fibrinolysis 14 day prior randomization 5 . Administration glycoprotein IIa/IIIb inhibitor 24 hour prior randomization 6 . Administration Low Molecular Weight Heparin ( LMWH ) 8 hour prior randomization 7 . Actual oral anticoagulant treatment 8 . Suspected AMI secondary occlusion one lesion treat previously percutaneous coronary intervention ( within previous 30 day angioplasty conventional stent within previous 12 month coat stent ) 9 . Dementia acute confusional state time randomization 10 . Subject incapacity unwillingness give inform consent -at least , verbally 11 . Known renal failure ( basal creatinine &gt; 2,5 mg/dl ) 12 . Reduced life expectancy ( &lt; 12 month ) due advance terminal concomitant condition 13 . Subject participation another clinical trial ( assess drug device ) 30 day prior randomization Diagnostic criterion pathology study Patients diagnosis AMI presenting : - Chest pain symptom myocardial ischemia , least , 20 minute duration , respond nitrate therapy evolution period le 6 hour symptom onset randomization process , , least , one follow alteration : - ST-elevation &gt; =2 mm 2 precordial lead - ST-elevation &gt; =1 mm 2 anterior lead - Complete de novo ( probably de novo ) leave bundle branch block ( LBBB ) Estimate sample size For follow condition : α = 0.05 ( 2 tail ) , power : 80 % ( β = 0.20 ) assume composite event incidence rate ( death , reinfarction disable CVA ) base previous registry ( 21.7 % fibrinolysis group 12.8 % PA group ) , sample size 282 patient per group need demonstrate difference ( 8.9 % absolute term 40 % relative term ) . Assuming loss follow-up rate 1 % , total number 570 patient Estimated loss patient prior randomization During period 3 month patient meet inclusion criterion , reason , enrol study include registry abbreviate CRF record inclusion/exclusion criterion , reason non-enrollment follow-up 30 day 12 month .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Tenecteplase</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Subjects 75 year age 2 . Diagnosis AMI : chest pain symptom myocardial ischemia , least , 20 minute duration , respond nitrate therapy , evolution period le 6 hour symptom onset randomization process , , least , one follow alteration : 1 . STelevation &gt; =2 mm 2 precordial lead 2 . STelevation &gt; =1 mm 2 anterior lead 3 . Complete de novo ( probably de novo ) leave bundle branch block ( LBBB ) 3 . Subject able give inform consent prior randomization process agree fulfill procedure describe protocol , include followup hospital discharge . A write consent sign close relative witness also acceptable . EXCLUSION CRITERIA : 1 . Documented contraindication use fibrinolytics . 1.1 . Internal active bleeding know history hemorrhagic diathesis 1.2 . History previous CVA kind time 1.3 . Intracranial tumor , arteriovenous malformation , aneurysm cerebral aneurysm repair 1.4 . Major surgery , parenchymal biopsy , ocular surgery severe traumatism 6 week prior randomization 1.5 . Unexplained puncture noncompressible vascular location last 24 hour prior randomization 1.6 . Confirmed arterial hypertension reliable measurement systolic AP &gt; 180 mmHg diastolic AP &gt; 110 mmHg 1.7 . Known thrombocytopenia &lt; 100.000 platelets/mL 1.8 . Prolonged ( &gt; 20 minute ) traumatic cardiopulmonar resuscitation ( CPR ) 2 week prior randomization 1.9 . History sign suggest aortic dissection 2 . Cardiogenic shock 3 . Estimated doortoneedle time &gt; 120 minute 4 . Administration fibrinolysis 14 day prior randomization 5 . Administration glycoprotein IIa/IIIb inhibitor 24 hour prior randomization 6 . Administration Low Molecular Weight Heparin ( LMWH ) 8 hour prior randomization 7 . Actual oral anticoagulant treatment 8 . Suspected AMI secondary occlusion one lesion treat previously percutaneous coronary intervention ( within previous 30 day angioplasty conventional stent within previous 12 month coat stent ) 9 . Dementia acute confusional state time randomization 10 . Subject incapacity unwillingness give inform consent least , verbally 11 . Known renal failure ( basal creatinine &gt; 2,5 mg/dl ) 12 . Reduced life expectancy ( &lt; 12 month ) due advance terminal concomitant condition 13 . Subject participation another clinical trial ( assess drug device ) 30 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acute myocardial infarction</keyword>
	<keyword>Elderly</keyword>
	<keyword>Thrombolysis</keyword>
	<keyword>Primary angioplasty</keyword>
	<keyword>Randomized trial</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>